Tag Archives: SHPG

Top 10 Blue Chip Stocks To Invest In Right Now

January 10, 2017: Markets opened mixed again Tuesday as the blue chips got off to a slow start. The DJIA peake in the middle of the day and slid back into the red with about an hour left this afternoon. The Nasdaq even posted another all-time high at 5,564.25 early this afternoon. Healthcare and financials were leading sectors while real-estate and energy lagged. WTI crude oil for February delivery settled at $50.82 a barrel, down about 2.2% on the day. February gold added less than 0.1% on the day to settle at $1,185.50. Equities were headed for a slightly higher close shortly before the bell as the DJIA traded up 0.05% for the day, the S&P 500 traded up 0.09%, and the Nasdaq Composite traded up 0.38%.

Stocks traded very near the break even line and the closing bell might see some shifts in which side of the line the indexes close on.

The DJIA stock posting the largest daily percentage gain ahead of the close Tuesday was Caterpillar Inc. (NYSE: CAT) which traded up about 1.93% at $94.15. The stock’s 52-week range is $56.36 to $97.40 Volume was about 35% below the daily average of around 4.2 million shares. The company had no specific news Tuesday.

Top 10 Blue Chip Stocks To Invest In Right Now: Ellie Mae, Inc.(ELLI)

Advisors’ Opinion:

  • [By Brian Stoffel]

    For a long time, low rates were a huge boon to Ellie Mae (NYSE:ELLI), which offers subscribers access to the Encompass platform. Encompass helps streamline the mortgage origination process.

  • [By Lee Jackson]

    These companies also reported insider selling last week:Corcept Therapeutics Inc. (NASDAQ: CORT), Customers Bancorp Inc. (NYSE: CUBI), Ellie Mae Inc. (NYSE: ELLI), Fiserv Inc. (NASDAQ: FISV) and Ulta Beauty Inc. (NASDAQ: ULTA).

  • [By WWW.THESTREET.COM]

    Ellie Mae (ELLI) was downgraded to sector perform from outperform at RBC Capital. $90 price target. The company is leveraged to lower expected refinance activity, RBC said. 

  • [By Jason Hall, Brian Stoffel, and Brian Feroldi]

    With that idea in mind, we asked three of our top contributors to write about a stock they see as being a bargain today, and they gave us mortgage industry software lynchpinEllie Mae Inc(NYSE:ELLI), real estate holding companyStore Capital Corp(NYSE:STOR), and steelmaker extraordinaireNucor Corporation(NYSE:NUE).

  • [By Brian Stoffel]

    HR and payroll specialist Paycom Software (NYSE:PAYC), mortgage software provider Ellie Mae (NYSE:ELLI), and cloud computing king for drug companies Veeva Systems (NYSE:VEEV) are the three best software companies you could buy in 2017. They share three key traits that any investor can love: high switching costs, blazing growth rates, and founders or CEOs with lots of skin in the game.

Top 10 Blue Chip Stocks To Invest In Right Now: Rackspace Hosting Inc(RAX)

Advisors’ Opinion:

  • [By Monica Gerson]

    Rackspace Hosting, Inc. (NYSE: RAX) reported better-than-expected earnings for the first quarter, but the company missed analysts’ sales estimates. Rackspace shares dropped 7.72 percent to $20.80 in the after-hours trading session.

Top 10 Blue Chip Stocks To Invest In Right Now: Telefonica SA(TEF)

Advisors’ Opinion:

  • [By Javier Hasse]

    Multiple-award-winning Trimaker is the leader in terms of sales in 3D printing in the region, serving clients like Staples, Inc. (NASDAQ: SPLS), Toyota Motor Corp (ADR) (NYSE: TM), Kraft Heinz Co (NASDAQ: KHC) and Telefonica S.A. (ADR) (NYSE: TEF). The company not only manufactures its own 3D printers, but also offers materials and related services.

  • [By Lisa Levin]

    Telecommunications services shares gained around 0.98 percent in trading on Thursday. Meanwhile, top gainers in the sector included Telefonica S.A. (ADR) (NYSE: TEF), and Allot Communications Ltd (NASDAQ: ALLT).

Top 10 Blue Chip Stocks To Invest In Right Now: YPF Sociedad Anonima(YPF)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of Knighthead Capital Management, LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Knighthead+Capital+Management%2C+LLC

    These are the top 5 holdings of Knighthead Capital Management, LLCSPDR S&P 500 (SPY) – 1,500,000 shares, 57.03% of the total portfolio. Spirit Realty Capital Inc (SRC) – 9,113,000 shares, 11.82% of the total portfolio. New PositionYPF SA (YPF) – 2,153,795 shares, 7.26% of the total portfolio. Shares reduced by 1.5%TerraForm Global Inc (GLBL) – 9,200,000 shares, 6.61% of the total portfolio. EQT Corp (EQT) – 597,300 shares, 5.9% of the total p

Top 10 Blue Chip Stocks To Invest In Right Now: Shire plc(SHPG)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Specialty pharmaceuticals Shire (SHPG) and Mallinckrodt (MNK) soared today following their better-than-expected earnings, while Morgan Stanley worried about Valeant Pharmaceutical International’s (VRX) ability to sell its unwanted assets.

  • [By Todd Campbell]

    The partnered portfolio includes Movantik and Adynovate, which are licensed to AstraZeneca (NYSE:AZN) and Shire (NASDAQ:SHPG), respectively.

    Movantik won Food and Drug Administration approval in September 2014 for use in relievingopioid constipation, and Nektar Therapeutics reports that annual prescriptions jumped 270% year over year in 2016. Currently, Movantik is selling at an annualized clip of about $160 million, and according to the licensing agreement, Nektar Therapeutics receives a 20% plus royalty on U.S. sales, plus potential sales milestone payments.

  • [By Jim Robertson]

    That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

    From May 2010 to May 2015, she was the VP, Regulatory Affairs at AbbVie Inc (NYSE: ABBV) leading the executive functions related to regulatory policy and intelligence. From August 1993 to January 2005, she held positions of increasing responsibility with Pfizer Inc (NYSE: PFE), formerly Wyeth.  From January 2005 to April 2010, she held positions with Shire PLC (NASDAQ: SHPG), including serving as Senior Director, Regulatory Affairs. This included responsibilities as Therapeutic Area Head for Shire’s Gastrointestinal Business Unit, Regulatory Advertising & Promotion and CMC. Rockney led the regulatory team and negotiations with the FDA for LIALDA which are part of the drug class of aminosalicylates that are now part of the clinical standard-of-care for treating inflammatory bowel disease. LIALDA™ was found to be effective in Phase 3 trials for inducing remission of active mild-to-moderate ulcerative colitis after eight weeks of treatment. LIALDA™ (also now marketed as Mezavant®) had 2016 U.S. sales of $714 million – up 16% relative to 2015 sales.

    Rockney’s work for Shire is of particular interest to Vitality Biopharma which has developed a new class of cannabinoid prodrugs (medications or compounds that, after administration, are converted within the body into a pharmacologically active drug), known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Cannabosides could provide therapeutic benefits for infl

  • [By Max Macaluso and David Williamson]

    At the end of last week, a Bloomberg article revealed that Shire (NASDAQ: SHPG  ) and pharmaceutical giant Sanofi (NYSE: SNY  ) may be circling ViroPharma (NASDAQ: VPHM  ) . The the following video, from The Motley Fool’s health care show Market Checkup, analysts David Williamson and Max Macaluso take a close look at ViroPharma and discuss the recent interest in this small biotech company.

  • [By Ben Levisohn]

    We highlight the key takeaways below, which have read-throughs for brand drug companies we cover such asAllergan (AGN), Shire (SHPG), Valeant Pharmaceuticals International, Mallinckrodt,Endo International and Jazz Pharmaceuticals (JAZZ), among others.

Top 10 Blue Chip Stocks To Invest In Right Now: On Assignment Inc.(ASGN)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Thursday, our Under the Radar Moversnewslettersuggested suggested small cap employment services stockOn Assignment, Inc (NYSE: ASGN) as a short trade thats already turned profitable for us:

Top 10 Blue Chip Stocks To Invest In Right Now: Wyndham Worldwide Corp(WYN)

Advisors’ Opinion:

  • [By Lee Jackson]

    The chief financial officerat Wyndham Worldwide Corp. (NYSE: WYN) wasselling stock this past week. Thomas Conforti parted with 25,900 shares of the hotel giant at $82.41 apiece. The total for the trade was posted at $2 million. The shares closed Friday at $82.65. The 52-week range is $62.60 to $86.72, and the consensus price target is $90.

  • [By Lisa Levin]

    Wednesday afternoon, the cyclical consumer goods & services sector proved to be a source of strength for the market. Leading the sector was strength from Conn's Inc (NASDAQ: CONN) and Wyndham Worldwide Corporation (NYSE: WYN).

  • [By Travis Hoium]

    Shares of hotel brand Wyndham Worldwide Corporation (NYSE:WYN) jumped as much as 11.1% in trading Wednesday after reporting first-quarter 2017 earnings. At 3:45 p.m. EDT on Wall Street, shares were still up an impressive 9.6% on the day.

Top 10 Blue Chip Stocks To Invest In Right Now: Franklin Covey Company(FC)

Advisors’ Opinion:

  • [By Monica Gerson]

     

    Darden Restaurants, Inc. (NYSE: DRI) is estimated to report its quarterly earnings at $1.08 per share on revenue of $1.81 billion.
    ConAgra Foods Inc (NYSE: CAG) is expected to report its quarterly earnings at $0.52 per share on revenue of $2.89 billion.
    Paychex, Inc. (NASDAQ: PAYX) is projected to report its quarterly earnings at $0.49 per share on revenue of $751.52 million.
    Micron Technology, Inc. (NASDAQ: MU) is expected to post a quarterly loss at $0.09 per share on revenue of $2.95 billion.
    McCormick & Company, Incorporated (NYSE: MKC) is estimated to report its quarterly earnings at $0.74 per share on revenue of $1.06 billion.
    Constellation Brands, Inc. (NYSE: STZ) is expected to report its quarterly earnings at $1.51 per share.
    Schnitzer Steel Industries, Inc. (NASDAQ: SCHN) is estimated to report its quarterly earnings at $0.18 per share on revenue of $356.41 million.
    Franklin Covey Co. (NYSE: FC) is expected to post its quarterly earnings at $0.08 per share on revenue of $49.89 million.
    Lindsay Corporation (NYSE: LNN) is projected to report its quarterly earnings at $0.99 per share on revenue of $148.43 million.

    Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

Top 10 Blue Chip Stocks To Invest In Right Now: Liquidity Services Inc.(LQDT)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Liquidity Services Inc. (NASDAQ: LQDT) was raised to Buy from Underperform, and the price target was raised up to $45 from $28.50, at Merrill Lynch.

  • [By Roberto Pedone]

    Liquidity Service (LQDT) is an online auction marketplace for surplus and salvage assets. This stock closed up 14.9% at $34.44 in Monday’s trading session.

    Monday’s Volume: 1.60 million

    Three-Month Average Volume: 402,622

    Volume % Change: 336%

    From a technical perspective, LQDT skyrocketed higher here right off its 50-day moving average of $30.94 with strong upside volume. This move briefly saw shares of LQDT trend back above its 200-day moving average at $34.60, before it closed just below that level at $34.44. Shares of LQDT are now quickly moving within range of triggering a big breakout trade. That trade will hit if LQDT manages to take out Monday’s intraday high of $35.21 and then once it clears some more near-term overhead resistance at $35.71 with high volume.

    Traders should now look for long-biased trades in LQDT as long as it’s trending above $32.67 or above $31.60 and then once it sustains a move or close above those breakout levels with volume that hits near or above 402,622 shares. If we get that breakout soon, then LQDT will set up to re-test or possibly take out its next major overhead resistance levels at $38 to $40.90.

Top 10 Blue Chip Stocks To Invest In Right Now: Versar, Inc.(VSR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Versar Inc. (NYSE: VSR) were down 36 percent to $1.61. Versar reported a Q3 loss of $1.34 per share on revenue of $36.5 million.

    Breitburn Energy Partners LP (NASDAQ: BBEP) was down, falling around 70 percent to $0.0580 as the company filed for Chapter 11 bankruptcy protection.

  • [By Lisa Levin]

    Versar Inc. (NYSE: VSR) shares shot up 37 percent to $1.55 after the company disclosed that its long-term joint venture with Johnson Controls Federal Systems was awarded up to $950 million IDIQ contract with U.S. Air Force.

Top 5 Low Price Stocks To Invest In 2018

The recent earning announcement on May 31, 2017 created sudden fear in the public’s mind and brought the stock price of Michael Kors (NYSE:KORS) down by around 9% in one day. As of this writing, the price remains at $33. In this article, I will discuss one negative and five positives, and explain why you should consider buying the stock at this low price.

One Negative

One negative, but a big one, that dragged down the stock price was the earning disappointment mainly driven by the macroeconomic situations in retail sector.

The entire retail sector has faced strong headwinds in recent years due to the emergence of online retailers (predominantly Amazon (NASDAQ:AMZN)), a strong dollar and a reduced number of tourists shopping in the U.S. The affected companies include Macy’s (NYSE:M), JCPenny (NYSE:JCP), Coach (NYSE:COH), Michael Kors, etc. The negative trends have driven down the stock price of the affected companies significantly in recent years, and the concern is legitimate in general,

Top 5 Low Price Stocks To Invest In 2018: Affimed N.V.(AFMD)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Affimed NV (NASDAQ: AFMD) were down around 21 percent to $1.70. Affimed priced its public offering of 10,000,000 of its common shares at $1.80 per common share.

  • [By Lisa Levin] Gainers
    Marathon Patent Group Inc (NASDAQ: MARA) shares rose 47.1 percent to $3.22 in pre-market trading after jumping 54.23 percent on Wednesday.
    Digital Power Corporation (NYSE: DPW) rose 27.6 percent to $0.800 in pre-market trading after gaining 9.79 percent on Wednesday.
    Social Reality Inc (NASDAQ: SRAX) shares rose 23.1 percent to $7.16 in the pre-market trading session after surging 37.59 percent on Wednesday.
    China Auto Logistics Inc (NASDAQ: CALA) rose 16.9 percent to $4.15 in pre-market trading after gaining 4.11 percent on Wednesday.
    Riot Blockchain Inc (NASDAQ: RIOT) rose 15.1 percent to $18.40 in pre-market trading after climbing 42.01 percent on Wednesday.
    Seven Stars Cloud Group Inc (NASDAQ: SSC) rose 14.5 percent to $2.85 in the pre-market trading session after gaining 0.40 percent on Wednesday.
    Affimed NV (NASDAQ: AFMD) shares rose 14.3 percent to $2.40 in pre-market trading after gaining 4.88 percent on Wednesday.
    Corecivic Inc (NYSE: CXW) rose 10.2 percent to $25.56 in pre-market trading after climbing 0.65 percent on Wednesday.
    LM Funding America, Inc. (NASDAQ: LMFA) rose 9.6 percent to $3.30 in pre-market trading after surging 34.98 percent on Wednesday.
    U.S. Global Investors, Inc. (NASDAQ: GROW) rose 7.2 percent to $3.30 in pre-market trading after dropping 8.06 percent on Wednesday.
    Xunlei Ltd (NASDAQ: XNET) rose 6.8 percent to $25.61 in pre-market trading after climbing 11.74 percent on Wednesday.
    Net 1 UEPS Technologies Inc (NASDAQ: UEPS) shares rose 5.9 percent to $13.00 in pre-market trading after gaining 21.34 percent on Wednesday.
    Addus Homecare Corporation (NASDAQ: ADUS) rose 5.5 percent to $35.60 in pre-market trading after gaining 3.69 percent on Wednesday.
    TOP SHIPS Inc (NASDAQ: TOPS) rose 5.2 percent to $0.528 in pre-market trading after falling 10.36 percent on Wednesday.
    Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) rose 4.7 percent to $14.11 in pre-market trading. Teva Pharma

Top 5 Low Price Stocks To Invest In 2018: Shire plc(SHPG)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Specialty pharmaceuticals Shire (SHPG) and Mallinckrodt (MNK) soared today following their better-than-expected earnings, while Morgan Stanley worried about Valeant Pharmaceutical International’s (VRX) ability to sell its unwanted assets.

  • [By Jim Robertson]

    That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

    From May 2010 to May 2015, she was the VP, Regulatory Affairs at AbbVie Inc (NYSE: ABBV) leading the executive functions related to regulatory policy and intelligence. From August 1993 to January 2005, she held positions of increasing responsibility with Pfizer Inc (NYSE: PFE), formerly Wyeth.  From January 2005 to April 2010, she held positions with Shire PLC (NASDAQ: SHPG), including serving as Senior Director, Regulatory Affairs. This included responsibilities as Therapeutic Area Head for Shire’s Gastrointestinal Business Unit, Regulatory Advertising & Promotion and CMC. Rockney led the regulatory team and negotiations with the FDA for LIALDA which are part of the drug class of aminosalicylates that are now part of the clinical standard-of-care for treating inflammatory bowel disease. LIALDA™ was found to be effective in Phase 3 trials for inducing remission of active mild-to-moderate ulcerative colitis after eight weeks of treatment. LIALDA™ (also now marketed as Mezavant®) had 2016 U.S. sales of $714 million – up 16% relative to 2015 sales.

    Rockney’s work for Shire is of particular interest to Vitality Biopharma which has developed a new class of cannabinoid prodrugs (medications or compounds that, after administration, are converted within the body into a pharmacologically active drug), known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Cannabosides could provide therapeutic benefits for infl

  • [By Max Macaluso and David Williamson]

    At the end of last week, a Bloomberg article revealed that Shire (NASDAQ: SHPG  ) and pharmaceutical giant Sanofi (NYSE: SNY  ) may be circling ViroPharma (NASDAQ: VPHM  ) . The the following video, from The Motley Fool’s health care show Market Checkup, analysts David Williamson and Max Macaluso take a close look at ViroPharma and discuss the recent interest in this small biotech company.

  • [By Ben Levisohn]

    We highlight the key takeaways below, which have read-throughs for brand drug companies we cover such asAllergan (AGN), Shire (SHPG), Valeant Pharmaceuticals International, Mallinckrodt,Endo International and Jazz Pharmaceuticals (JAZZ), among others.

Top 5 Low Price Stocks To Invest In 2018: iShares MSCI All Peru Capped ETF (EPU)

Advisors’ Opinion:

  • [By Andrew Efimoff] Related Some Positive Indexing News For A Frontier Markets ETF Why The Frontier Markets ETF Slumped Last Year Status Quo Decisions Would Bode Well For PAK ETF (Seeking Alpha)
    Related EPU Peru ETF Confronts Politics Commodities Call For The Colombia ETF Graċ¸½a Y Montero May Have Peaked In 2016 (Seeking Alpha) Gainers Pakistan: Global XMSCI Pakistan ETF (NYSE: PAK) is up 5.67 percent after receiving MSCI’s Emerging Markets Index approval. Peru: iShares MSCI All Peru Capped Index Fund(NYSE: EPU) is up 2.15 percent after Kuzynski won Peru’s nail-biting election. Philippines: iShares MSCI Philippines Investable(NYSE: EPHE) is up 2.21 percent after Macquarie Research said President Elect Rodrigo Duterte would lift the Pilipino property market. India: iShares MSCI India ETF (NYSE: INDA) is up 1.96 percent after India’s government relaxed regulation, making it easier for domestic airlines to fly overseas.

    Related Link: Some Positive Indexing News For A Frontier Markets ETF

  • [By Todd Shriber, ETF Professor]

    ARGT, the lone exchange traded fund dedicated to Argentine equities, is up 19.6 percent year-to-date. That is good for the second-best showing among Latin America single-country ETFs, trailing only the iShares MSCI Capped Peru Index Fund (NYSE: EPU).

Top 5 Low Price Stocks To Invest In 2018: Plantronics Inc.(PLT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Plantronics Inc (NYSE: PLT) were down 25 percent to $33.36. Plantronics reported better-than-expected third-quarter earnings, but the company’s revenue missed analysts’ expectations. The company announced a new 1 million share buyback plan and issued a weak earnings forecast for the fourth quarter.

Top 5 Low Price Stocks To Invest In 2018: Utilities Select Sector SPDR ETF (XLU)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    The Dow utility average ended last week at a stabilizing 639.95 after trading as low as 616.19 on Nov. 14. Keep in mind that a “death cross” was confirmed on election day, when the 50-day simple moving average fell below the 200-day simple moving average, indicating that lower prices are likely ahead. The 200-day is now at 666.30. The utility average has returned to my range of key levels of 635.23 and 670.81, which remain magnets for the remainder of 2016. This week’s value level is above the Nov. 14 low at 620.87. Investors seeking the safety of dividends can trade the Utilities Select Sector SPDR Fund (XLU) , which is a basket of 28 utility stocks.

  • [By WWW.MONEYSHOW.COM]

    With a little more than $6 billion in assets and average daily trading volumes in excess of 12 million shares per day, SPDR Utilities (XLU) is the top choice to hold during Utilities seasonally favorable period. It has a gross expense ratio of just 0.14% and comes with the added kicker of a 3.37% dividend yield.

  • [By Craig Jones]

    Speaking on Bloomberg Markets, Kevin Kelly of Recon Capital Partners suggested that investors with a long position in Utilities SPDR (ETF) (NYSE: XLU) should consider an options strategy that offers protection ahead of the FOMC meeting.

  • [By Craig Jones]

    On CNBC's Options Action, Dan Nathan suggested a bearish options trading idea in Utilities SPDR (ETF) (NYSE: XLU).

    The stock caught his attention, because he noticed a big put options volume last week in the name. He thinks traders should not be in the stock ahead of a possible rate hike.

Top 10 Bank Stocks To Buy For 2018

Westlake Village, CA, based Investment company One Capital Management, LLC buys iShares S&P SmallCap 600 Growth, iShares S&P SmallCap 600 Value, Bristol-Myers Squibb Company, iShares Core S&P Small-Cap, SPDR S&P 400 Mid Cap Growth ETF (based on S&P MidC, BP PLC, Coca-Cola Co, Bank of Nova Scotia, US Bancorp, 3M Co, sells iShares Russell 2000 Value, iShares Russell 2000 Growth, iShares China Large-Cap, Teck Resources, iShares Russell 2000 during the 3-months ended 2017-03-31, according to the most recent filings of the investment company, One Capital Management, LLC. As of 2017-03-31, One Capital Management, LLC owns 123 stocks with a total value of $315 million. These are the details of the buys and sells.

New Purchases: MDYG, KO, BNS, USB, MMM, Added Positions: IJT, IJS, BMY, IJR, SCHF, BP, SCHE, PG, VWO, CVX, Reduced Positions: IWN, IWO, FXI, TECK, IWC, IWM, IWS, BAC, SCHG, IWP, Sold Out: ORCL, ABBV, RSP, EGY,

For the details of One Capital Management, LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=One+Capital+Management%2C+LLC

Top 10 Bank Stocks To Buy For 2018: 8point3 Energy Partners LP(CAFD)

Advisors’ Opinion:

  • [By Shanthi Rexaline]

    If the Suniva noise is removed, the firm believes First Solar stock becomes a fundamental story of execution and long-term share gains. The firm also noted that the company has found success selling off projects to third parties, as intended, with the management seeing more value in selling to third-parties rather than to 8Point3 Energy Partners LP (NASDAQ: CAFD).

  • [By Travis Hoium]

    Leading the charge are two yieldcos — NextEra Energy Partners (NYSE:NEP) and 8point3 Energy Partners (NASDAQ:CAFD) — and utility company AES Corporation (NYSE:AES). Here’s a look at why they’re good dividend stocks to own today.

  • [By J.B. Maverick]

    Recently added in January 2016 to the "strong buy" list at Zacks Investment Research, 8point3 Energy Partners LP (NASDAQ: CAFD) is a subsidiary firm with the support of major solar power companies SunPower and First Solar, and plenty of cash to fund 2016 growth projects. It should be well positioned to move forward in its business of acquiring and operating solar energy generation projects. In late January 2016, the stock is trading at $16.45, in the middle of its 52-week range of $10.26 to $21.15. The stock offers a dividend yield of 2.39%. It has been in a general uptrend since October 2015. Year to date in 2016, the stock is down 2.97%, which means it is weathering the market storm better than many other firms. With the backing of First Solar and SunPower, and a partnership agreement with Wells Fargo, 8point3 is in a stronger industry position than the majority of alternative energy companies.

  • [By Travis Hoium]

    Axiom Capital Management’s Gordon Johnson made a startling comparison this week, saying that yieldco 8point3 Energy Partners (NASDAQ:CAFD) looks a lot like the now bankrupt SunEdison and the recently bailed-out SolarCity. If he’s right and the yieldco is built on unstable ground, it could justify the stock’s drop over the last few months and be a warning for investors.

Top 10 Bank Stocks To Buy For 2018: Colliers International Group Inc. (CIGI)

Advisors’ Opinion:

  • [By Lee Jackson]

    A10% owner of Colliers International Group Inc. (NASDAQ: CIGI) wasadding to holdings last week. Spruce House Partners bought a total of 133,800 shares of the company at $42.05 per share. The total for the buy was listed at $6 million.

Top 10 Bank Stocks To Buy For 2018: Castlight Health, inc.(CSLT)

Advisors’ Opinion:

  • [By Todd Campbell]

    Castlight Health (NYSE:CSLT)share price climbed 13.2% Wednesday after an SEC filing revealed that Maverick Capital had significantly boosted its stake in the company to 10.6%.

Top 10 Bank Stocks To Buy For 2018: Green Mountain Coffee Roasters Inc.(GMCR)

Advisors’ Opinion:

  • [By David Sterman]

    But for short sellers in Green Mountain Coffee Roasters (Nasdaq: GMCR), there's another outcome: They've been badly burned as shares have surged, but they insist they've been right all along, and it's only a matter of time before the stock crashes and burns.

  • [By Canadian Value]

    So Im going to stick my next out and share my views on four battleground stocks that are among my favorite shorts: World Acceptance (WRLD), Green Mountain (GMCR), Herbalife (HLF), and InterOil (IOC). And next week at the Value Investing Congress I will present another short, my largest.

  • [By Jonas Elmerraji]

    As badly as short sellers want to hate on Green Mountain Coffee Roasters (GMCR), betting against the multiyear rally in this $12.7 billion beverage stock has been about as wise as eating from a box with a skull and crossbones on it. And as a bull market continues to lift all ships, Green Mountain’s ship is going to keep floating above the others.

    Green Mountain owns Keurig, the brand of beverage brewers that use self-contained K-Cups to make coffee, teas, and other drinks. While Keurig’s “fad” status has certainly helped tip the deck against GMCR, the fact remains that the firm has done most of the hard work in getting Keurig machines accepted by consumers. With brewers essentially ubiquitous at this point, the firm is able to make money on its cash cow: the K-Cups.

    Keurig’s individual-serving cups have big margins and a big installed base. With huge convenience and the relatively large sunk cost that consumers have put into their Keurig machines, it’s a sticky business with big switching costs. Consumers who buy a Keurig are much less likely to spend the money on a competing brand of proprietary coffee pods.

    I’ve said before that GMCR is far from cheap right now. But its momentum trajectory is showing few signs of fizzling out, especially as direct competitors such as Starbucks (SBUX) continue to sell K-Cups of their own. Don’t bet against GMCR in September – buy this Rocket Stock instead.

Top 10 Bank Stocks To Buy For 2018: Zynga Inc.(ZNGA)

Advisors’ Opinion:

  • [By Shanthi Rexaline]

    Most tech companies opt to have the dual class structure with the primary motive of retaining voting control. Facebook Inc (NASDAQ: FB), Zynga Inc (NASDAQ: ZNGA), Groupon Inc (NASDAQ: GRPN) and Box Inc (NYSE: BOX) are a few companies who went the dual class stock structure way.

  • [By Peter Graham]

    Small cap social media gaming stockZynga Inc (NASDAQ: ZNGA) reportedQ2 2017 earnings after the Wednesday market close. Revenue was above guidance by $9.2 million and up 15% year-over-year to $209.2 million whilenet income was $5.1 million, better than guidance by $11.1 million and an improvement of $9.5 million year-over-year.

  • [By Peter Graham]

    The Q4 2016 earnings report for small cap social media gaming stockZynga Inc (NASDAQ: ZNGA) is scheduled for after the market closes on Thursday (February 9th). Our SmallCap Network Elite Opportunity (SCN EO) portfolio has repeated suggested trading Zynga Inc with aJanuary 2014 SCN EO newsletter noting the following:

  • [By Andrew Tonner]

    IPOs like Snap are a rare breed. In looking for companies comparable to it, I looked for listings that sported a post-IPO valuation above $5 billion, went pubic after 2010, and employ a consumer-facing business model. This resulted in an admittedly small sample of highly hyped tech IPOs including Facebook (NASDAQ:FB), Twitter (NYSE:TWTR), Groupon (NASDAQ:GRPN), and Zynga (NASDAQ:ZNGA). For transparency’s sake, I opted to not include Chinese e-commerce giant Alibaba in this list because its geographic focus and scale made it fundamentally different than the above tech IPOs, although including it wouldn’t have changed the outcome of this analysis.

  • [By Peter Graham]

    A long term performance chart shows shares of Glu Mobile all over the place for investors (but savvy traders could have profitably traded shares) whilepeer Zynga Inc (NASDAQ: ZNGA) has mostly underperformed after the initial surge wore off:

Top 10 Bank Stocks To Buy For 2018: Cliffs Natural Resources Inc.(CLF)

Advisors’ Opinion:

  • [By Lisa Levin]

    Basic materials shares rose by 0.74 percent in the US market on Friday. Top gainers in the sector included AK Steel Holding Corporation (NYSE: AKS), Cliffs Natural Resources Inc (NYSE: CLF), and United States Steel Corporation (NYSE: X).

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Wednesday's regular session.

  • [By Wayne Duggan]

    The best candidates for window dressing trades this week include the top 2016 performers Teck Resources Ltd (USA) (NYSE: TECK), Cliffs Natural Resources Inc (NYSE: CLF) and AK Steel Holding Corporation (NYSE: AKS).

Top 10 Bank Stocks To Buy For 2018: Natural Grocers by Vitamin Cottage, Inc.(NGVC)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart for Whole Foods Market shows shares still lower than they were five years ago whilepeers in the organic space like Sprouts Farmers Market Inc (NASDAQ: SFM) and Natural Grocers by Vitamin Cottage (NYSE: NGVC) have performed worst:

  • [By Peter Graham]

    A long term performance chart for Whole Foods Market shows along with mid cap peerSprouts Farmers Market Inc (NASDAQ: SFM) and Natural Grocers by Vitamin Cottage (NYSE: NGVC) appearing to all be in downtrends that may or may not have leveled off:

  • [By Lisa Levin]

    Natural Grocers by Vitamin Cottage Inc (NYSE: NGVC) was down, falling around 33 percent to $5.70 as the company posted downbeat quarterly results and lowered its FY17 earnings guidance.

  • [By Peter Graham]

    A long term performance chart for Whole Foods Market shows along with mid cap peerSprouts Farmers Market Inc (NASDAQ: SFM) and Natural Grocers by Vitamin Cottage (NYSE: NGVC) largely drifting lower with two price spikes:

Top 10 Bank Stocks To Buy For 2018: Clear Channel Outdoor Holdings, Inc.(CCO)

Advisors’ Opinion:

  • [By Sara Cornell]

    The agreement between the two companies allows Azincourt to option up to 70% of the East Preston property located in the Athabasca Basin. Home to Cameco’s (TSX:CCO) McArthur River uranium mine, the Athabasca Basin is considered one of the richest sources of uranium in the world, with many uranium deposits hosting grades substantially higher than the world average grade. The area has been a hotbed for energy metal investors over the past few years, due to significant high grade uranium discoveries by large cap mining companies.

Top 10 Bank Stocks To Buy For 2018: Avid Technology Inc.(AVID)

Advisors’ Opinion:

  • [By Anders Bylund]

    Shares of Avid Technology(NASDAQ:AVID) rose 20.3% in April 2017, according to data from S&P Global Market Intelligence.

    So what

    Last month’s share price surge rested on Avid’s release of a coherent cloud-based media production suite. The new version of Avid’s MediaCentral platform takes advantage of the cloud, central storage, and back-end data processing in a way older versions never attempted, modernizing the media production tool in a big way.

  • [By Monica Gerson]

    Avid Technology, Inc. (NASDAQ: AVID) is estimated to post its quarterly earnings at $0.36 per share on revenue of $144.02 million.

    Consolidated Water Co. Ltd. (NASDAQ: CWCO) is expected to post its quarterly earnings at $0.11 per share on revenue of $15.15 million.

  • [By Lisa Levin]

    Avid Technology, Inc. (NASDAQ: AVID) shares were also up, gaining 24 percent to $5.01 following Q3 results. Avid Technology reported Q3 earnings of $0.00 per share on revenue of $105.26 million.

Top 10 Bank Stocks To Buy For 2018: Shire plc(SHPG)

Advisors’ Opinion:

  • [By Max Macaluso and David Williamson]

    At the end of last week, a Bloomberg article revealed that Shire (NASDAQ: SHPG  ) and pharmaceutical giant Sanofi (NYSE: SNY  ) may be circling ViroPharma (NASDAQ: VPHM  ) . The the following video, from The Motley Fool’s health care show Market Checkup, analysts David Williamson and Max Macaluso take a close look at ViroPharma and discuss the recent interest in this small biotech company.

  • [By Ben Levisohn]

    Specialty pharmaceuticals Shire (SHPG) and Mallinckrodt (MNK) soared today following their better-than-expected earnings, while Morgan Stanley worried about Valeant Pharmaceutical International’s (VRX) ability to sell its unwanted assets.

  • [By Todd Campbell]

    The partnered portfolio includes Movantik and Adynovate, which are licensed to AstraZeneca (NYSE:AZN) and Shire (NASDAQ:SHPG), respectively.

    Movantik won Food and Drug Administration approval in September 2014 for use in relievingopioid constipation, and Nektar Therapeutics reports that annual prescriptions jumped 270% year over year in 2016. Currently, Movantik is selling at an annualized clip of about $160 million, and according to the licensing agreement, Nektar Therapeutics receives a 20% plus royalty on U.S. sales, plus potential sales milestone payments.

  • [By Ben Levisohn]

    We highlight the key takeaways below, which have read-throughs for brand drug companies we cover such asAllergan (AGN), Shire (SHPG), Valeant Pharmaceuticals International, Mallinckrodt,Endo International and Jazz Pharmaceuticals (JAZZ), among others.

Best Insurance Stocks To Invest In Right Now

31 Worst Paying College Majors: 2017

30 Best Paying College Majors: 2017

Distributions Out of a Cash Value Life Insurance Policy

Labor Secretary Alexander Acosta said Monday that Labor will not delay the fiduciary rule’s June 9 compliance date while the department seeks public input on the rule as laid out in President Donald Trump’s Feb. 3 memorandum.

“The Labor Department has concluded that it is necessary to seek additional public input on the entire fiduciary rule, and we will do so,” Acosta said in a Monday op-ed in The Wall Street Journal.

The RFI will specifically ask for public comment on whether it is likely to take more time to implement these new approaches than what the department envisioned when it set Jan. 1, 2018, as the applicability date for full compliance with all of the exemptions’ conditions, and, if so, whether an additional delay of that date would reduce burdens on financial services providers and benefit retirement investors by allowing for a smoother implementation of those market changes.

Best Insurance Stocks To Invest In Right Now: Shire plc(SHPG)

Advisors’ Opinion:

  • [By Max Macaluso and David Williamson]

    At the end of last week, a Bloomberg article revealed that Shire (NASDAQ: SHPG  ) and pharmaceutical giant Sanofi (NYSE: SNY  ) may be circling ViroPharma (NASDAQ: VPHM  ) . The the following video, from The Motley Fool’s health care show Market Checkup, analysts David Williamson and Max Macaluso take a close look at ViroPharma and discuss the recent interest in this small biotech company.

  • [By Jim Robertson]

    That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

    From May 2010 to May 2015, she was the VP, Regulatory Affairs at AbbVie Inc (NYSE: ABBV) leading the executive functions related to regulatory policy and intelligence. From August 1993 to January 2005, she held positions of increasing responsibility with Pfizer Inc (NYSE: PFE), formerly Wyeth.  From January 2005 to April 2010, she held positions with Shire PLC (NASDAQ: SHPG), including serving as Senior Director, Regulatory Affairs. This included responsibilities as Therapeutic Area Head for Shire’s Gastrointestinal Business Unit, Regulatory Advertising & Promotion and CMC. Rockney led the regulatory team and negotiations with the FDA for LIALDA which are part of the drug class of aminosalicylates that are now part of the clinical standard-of-care for treating inflammatory bowel disease. LIALDA™ was found to be effective in Phase 3 trials for inducing remission of active mild-to-moderate ulcerative colitis after eight weeks of treatment. LIALDA™ (also now marketed as Mezavant®) had 2016 U.S. sales of $714 million – up 16% relative to 2015 sales.

    Rockney’s work for Shire is of particular interest to Vitality Biopharma which has developed a new class of cannabinoid prodrugs (medications or compounds that, after administration, are converted within the body into a pharmacologically active drug), known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Cannabosides could provide therapeutic benefits for infl

  • [By Ben Levisohn]

    We highlight the key takeaways below, which have read-throughs for brand drug companies we cover such asAllergan (AGN), Shire (SHPG), Valeant Pharmaceuticals International, Mallinckrodt,Endo International and Jazz Pharmaceuticals (JAZZ), among others.

  • [By Todd Campbell]

    The partnered portfolio includes Movantik and Adynovate, which are licensed to AstraZeneca (NYSE:AZN) and Shire (NASDAQ:SHPG), respectively.

    Movantik won Food and Drug Administration approval in September 2014 for use in relievingopioid constipation, and Nektar Therapeutics reports that annual prescriptions jumped 270% year over year in 2016. Currently, Movantik is selling at an annualized clip of about $160 million, and according to the licensing agreement, Nektar Therapeutics receives a 20% plus royalty on U.S. sales, plus potential sales milestone payments.

  • [By Ben Levisohn]

    Specialty pharmaceuticals Shire (SHPG) and Mallinckrodt (MNK) soared today following their better-than-expected earnings, while Morgan Stanley worried about Valeant Pharmaceutical International’s (VRX) ability to sell its unwanted assets.

Best Insurance Stocks To Invest In Right Now: BioMarin Pharmaceutical Inc.(BMRN)

Advisors’ Opinion:

  • [By George Budwell, Rich Smith, and Matthew DiLallo]

    With this question in mind, we asked three of our contributors which stocks they recommend to buy and hold for the next 20 years. They suggestedBioMarin Pharmaceutical (NASDAQ:BMRN), Enterprise Products Partners (NYSE:EPD), andLockheed Martin (NYSE:LMT). Below, they discuss why they chose these particular stocks, and why investors with a long-term outlook may want to consider adding them to their portfolios right now.

  • [By Keith Speights]

    You might not have heard too much about Akebia Therapeutics (NASDAQ:AKBA), BioMarin Pharmaceutical (NASDAQ:BMRN), and Idera Pharmaceuticals (NASDAQ:IDRA). These are three biotech stocks that you could be overlooking — but deserve your attention. Here’s why.

  • [By Ben Levisohn]

    Skorney’s namesVertex Pharmaceuticals (VRTX),Sarepta Therapeutics (SRPT), and Curis (CRIS) his top biotech picks for 2017, while Ulz chosesBioMarin Pharmaceutical (BMRN) andParatek Pharmaceuticals (PRTK).

Best Insurance Stocks To Invest In Right Now: OncoMed Pharmaceuticals, Inc.(OMED)

Advisors’ Opinion:

  • [By Teresa Rivas]

    OncoMed Pharmaceuticals (OMED) has lost more than a third of its value Monday, after Bayer decided not to exercise its option to license the firms Phase II-ready WNT pathway inhibitors Vantictumab and Ipafricept, which treat pancreatic cancer.

    Pixabay

    That wasnt the only bad news, however, as the firms randomized-controlled Phase II “YOSEMITE” trial of pancreatic cancer drug demcizumab also missed its primary endpoint.

    Leerinks Michael Schmidt and his team reiterated a Market Perform rating on the stock Monday, and lowered their price target from $10 to $6 on the news, calling it a “double setback” for OncoMed.

    More detail from the note:

    This is a major setback for OMED and in our view for the cancer stem cell targets more broadly, which have been a difficult area of drug development. We’ve been cautious on the probability-of-success of these agents and see more promise on OMED’s recent efforts in building a second area of focus in immuno-oncology. Going forward, OMED plans to review and prioritize its R&D pipeline after results from the still pending tarextumab Phase II “PINNACLE” trial in small cell lung cancer (SCLC) and data from the demcizumab “DENALI” trial in NSCLC are available in 2Q17. We remain MP rated in light of the uncertainties around OMED’s pipeline and strategy at this point. We previously assigned a 30% probability of success (POS) to demcizumab which we now have removed from our model. We also think chances that CELG will opt-into this program are slim and we have removed associated POS-adjusted milestone payments from our model. OMED has cash to run operations through 3Q18.

    OncoMed is down 36.1% to $5.60 this afternoon.

  • [By Paul Ausick]

    OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped nearly 44% Monday to post a new 52-week low of $4.94 after closing Friday at $8.76. The stock’s 52-week high is $15.49. Volume of about 3.3 million shares was nearly 20 times the daily average of around 182,000. A proposed deal with Bayer AG fell through and one of the company’s drugs failed a phase 2 clinical trial.

  • [By Paul Ausick]

    OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped about 5.3% Wednesday to post a new 52-week low of $4.69 after closing at $4.95 on Tuesday. The stock’s 52-week high is $15.49. Volume was more than double the daily average of around 270,000 shares. The company had no specific news Wednesday.